ArticleAnnals of surgical oncology2026
Neoadjuvant Chemoimmunotherapy for Elderly Patients with Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study explored the safety and clinical efficacy of neoadjuvant immunotherapy combined with chemotherapy (NAIC) for elderly patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
methodsAll patients aged >70 years who underwent esophagectomy for locally advanced resectable ESCC in our hospital from February 2018 to June 2024 were retrospectively reviewed. Patients were classified into either a "surgery alone" group or an "NAIC plus surgery" group. In the NAIC plus surgery group, patients received two to four cycles of NAIC. The patients' clinical characteristics and outcomes were analyzed using a propensity score-matched comparison and a Cox regression model.
resultsOverall, 278 patients were included in the study, of whom 152 (54.7%) received NAIC. NAIC plus surgery was associated with better disease-free survival (DFS) and overall survival (OS) than surgery alone, including among patients aged >75 years. The perioperative outcomes and incidence rates of postoperative complications were similar between the two groups. Patients aged >75 years showed no increase in grade 3 or higher NAIC-related adverse events and no reduction in pathological tumor regression grade. In addition, multivariable analysis highlighted adjuvant therapy as a favorable factor for OS; however, in patients who received NAIC, major pathological response was independently associated with both DFS and OS, regardless of whether adjuvant therapy was received.
conclusionsThis study revealed that NAIC plus surgery is a safe and clinically effective treatment that improves survival in elderly patients with locally advanced resectable ESCC, including in carefully selected fit patients aged >75 years.
Indexed as
Identifiers
41251915What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.